Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$11.62 -2.8%	$11.78	$4.88 ▼ $19.58	$259.48M	N/A	82,020 shs	71,052 shs
INZY Inozyme Pharma	$4.00	$3.76	$0.72 ▼ $6.24	$258.25M	2.27	950,321 shs	N/A
IRD Opus Genetics	$1.13 -3.0%	$1.01	$0.65 ▼ $1.75	$69.51M	-0.02	507,539 shs	195,008 shs
PRQR ProQR Therapeutics	$2.26 -5.8%	$1.92	$1.07 ▼ $4.62	$252.51M	0.36	662,515 shs	280,471 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-2.84%	-4.52%	-3.81%	+66.00%	+1,161,999,900.00%
INZY Inozyme Pharma	0.00%	0.00%	+0.50%	+335.02%	-30.31%
IRD Opus Genetics	-3.00%	0.00%	+21.51%	+48.70%	+112,999,900.00%
PRQR ProQR Therapeutics	-5.83%	-2.59%	+16.49%	+98.25%	+23.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	3.518 of 5 stars	4.2	4.0	0.0	0.0	2.7	2.5	0.0
IRD Opus Genetics	1.6919 of 5 stars	3.5	0.0	0.0	0.0	2.1	0.0	0.6
PRQR ProQR Therapeutics	2.5992 of 5 stars	3.6	5.0	0.0	0.0	2.7	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	3.00	Buy	$33.00	183.99% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	193.75% Upside
IRD Opus Genetics	3.00	Buy	$7.33	548.97% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	253.98% Upside

Current Analyst Ratings Breakdown

Latest IRD, AARD, PRQR, and INZY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/30/2025	AARD Aardvark Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
6/27/2025	IRD Opus Genetics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/15/2025	AARD Aardvark Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$0.90 per share	N/A
IRD Opus Genetics	$13.65M	4.94	N/A	N/A	$0.21 per share	5.38
PRQR ProQR Therapeutics	$20.46M	11.62	N/A	N/A	$0.91 per share	2.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$20.59M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	-$102.02M	-$1.69	N/A	N/A	N/A	N/A	-159.93%	-82.48%	8/5/2025 (Estimated)
IRD Opus Genetics	-$57.53M	-$2.10	N/A	N/A	N/A	-429.42%	-283.28%	-144.32%	8/12/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/4/2025 (Estimated)

Latest IRD, AARD, PRQR, and INZY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	N/A	N/A	N/A	N/A	N/A
8/12/2025	N/A	IRD Opus Genetics	-$0.25	N/A	N/A	N/A	$4.27 million	N/A
8/5/2025	Q2 2025	INZY Inozyme Pharma	-$0.36	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	IRD Opus Genetics	-$0.34	-$0.32	+$0.02	-$0.24	$4.00 million	$4.30 million
5/14/2025	N/A	AARD Aardvark Therapeutics	-$0.70	-$0.71	-$0.01	-$0.71	N/A	N/A
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	25.86	25.86
INZY Inozyme Pharma	0.65	2.19	2.19
IRD Opus Genetics	N/A	1.98	1.98
PRQR ProQR Therapeutics	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
INZY Inozyme Pharma	88.30%
IRD Opus Genetics	14.97%
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	N/A
INZY Inozyme Pharma	12.18%
IRD Opus Genetics	6.60%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.70 million	N/A	N/A
INZY Inozyme Pharma	50	64.56 million	56.70 million	Optionable
IRD Opus Genetics	14	59.66 million	55.72 million	N/A
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable

IRD, AARD, PRQR, and INZY Headlines

Recent News About These Companies

ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI

July 12, 2025 | msn.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com

July 8, 2025 | investing.com

ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving Average - Here's Why

July 8, 2025 | marketbeat.com

PRQR - ProQR Therapeutics NV Sustainability - Morningstar

July 3, 2025 | morningstar.comM

PRQR - ProQR Therapeutics NV Key Metrics - Morningstar

July 2, 2025 | morningstar.comM

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Buy" from Brokerages

June 30, 2025 | marketbeat.com

ProQR Therapeutics NV (PRQR) Stock Forums - Investing.com

June 29, 2025 | investing.com

ProQR Therapeutics N.V. (PRQR) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

ProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 27, 2025 | finanznachrichten.de

ProQR Therapeutics' (PRQR) Market Outperform Rating Reiterated at JMP Securities

June 27, 2025 | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Receives "Overweight" Rating from Cantor Fitzgerald

June 27, 2025 | marketbeat.com

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 26, 2025 | globenewswire.com

ProQR Therapeutics Reports Q1 2025 Financial Results

June 2, 2025 | tipranks.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year

May 24, 2025 | investing.com

ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock News

May 13, 2025 | gurufocus.com

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 12, 2025 | globenewswire.com

ProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial Position

May 10, 2025 | nasdaq.com

ProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial Results

May 10, 2025 | finanznachrichten.de

ProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial Results

May 10, 2025 | finanznachrichten.de

New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)

May 10, 2025 | finance.yahoo.com

ProQR: Q1 Earnings Snapshot

May 10, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
By Chris Markoch | June 25, 2025
View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
Microsoft Stock Holds Steady as AI Drives Workforce Shift
By Chris Markoch | June 23, 2025
View Microsoft Stock Holds Steady as AI Drives Workforce Shift
Regional Bank Buybacks: 5 Institutions Making Big Moves
By Leo Miller | June 24, 2025
View Regional Bank Buybacks: 5 Institutions Making Big Moves
Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up
By Jordan Chussler | July 7, 2025
View Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up

IRD, AARD, PRQR, and INZY Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$11.62 -0.34 (-2.84%)

As of 07/18/2025 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)

As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Opus Genetics NASDAQ:IRD

$1.13 -0.04 (-3.00%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.15 +0.02 (+2.12%)

As of 07/18/2025 07:38 PM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

ProQR Therapeutics NASDAQ:PRQR

$2.26 -0.14 (-5.83%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.26 0.00 (-0.22%)

As of 07/18/2025 07:06 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time